

Date: 29th August, 2022

**BSE Limited** 

Corporate Relation Department PhirozeJeejeeboi Towers, Dalal Street, Mumbai - 400001.

Scrip Code: 524404

National Stock Exchangeof India Limited

Listing Department

Exchange Plaza, C-1, Block-G,

Bandra-Kurla Complex,

Bandra (East), Mumbai - 400051.

Symbol: MARKSANS

Sub: Outcome of the 30th Annual General Meeting held on Monday, 29th August, 2022. (AGM Commenced at 09:00 AM and Concluded at 09:45 AM)

Dear Sir,

This is to inform you as follows:

The shareholders of the Company have, at the 30<sup>th</sup> Annual General Meeting held today i.e. 29<sup>th</sup> August, 2022, through Video Conferencing:

- 1. Adopted the audited Financial Statements of the Company for the financial year ended 31<sup>st</sup> March, 2022 including audited Consolidated Financial Statements for the financial year ended 31<sup>st</sup> March, 2022, together with the Reports of the Board of Directors' and Auditors' thereon.
- 2. Declared dividend of Rs. 0.25 (i.e. 25%) on Equity Shares of Re. 1/- each face value and dividend of Rs. 7.00 (i.e. 7%) on Redeemable Cumulative Preference Shares of Rs.100/- each face value. The dividend will be paid on or after 20th September, 2022.
- 3. Approved re-appointment of Mrs. Sandra Saldanha (DIN: 00021023), who retired by rotation and being eligible, offered herself for re-appointment.
- 4. Approved appointment of Statutory Auditor to fill casual vacancy.
- 5. Approved appointment of M/s M S K A & Associates, Chartered Accountants as the Statutory Auditor for a consecutive period of five (5) years with effect from the conclusion of 30th Annual General Meeting till the conclusion of 35th Annual General Meeting.
- 6. Approved revision in remuneration of Mr. Mark Saldanha (DIN: 00020983), Managing Director of the Company.
- 7. Approved Marksans Employees Stock Option Scheme 2022.

You are requested to note the above in your records.

Thanking You.

Yours faithfully,

For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary
CIN: L24110MH1992PLC066364

www.marksanspharma.com